New diabetes pill shows promise in early trial
NCT ID NCT00628212
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 study tested a new drug called teneligliptin (MP-513) in 324 Japanese adults with type 2 diabetes. Participants took one of three doses of the drug or a placebo daily for 12 weeks. The main goal was to see how well the drug lowered blood sugar levels (HbA1c) and to check for side effects. The results will help determine the right dose for larger, confirmatory studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Takikawa-shi, Hokkaido, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Teneligliptin (also called MP-513), a drug taken once daily to lower blood sugar
What this could lead to
If successful, this could provide a new once-daily pill option to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is an early-phase trial with only 324 participants over 12 weeks. Long-term safety and effectiveness are not yet known, and results may not apply to non-Japanese populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.